An investigation on behalf of investors of AmerisourceBergen Corporation (NYSE: ABC) shares over potential securities laws violations by AmerisourceBergen and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AmerisourceBergen Corporation (NYSE: ABC) concerning whether a series of statements by AmerisourceBergen Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.


Chesterbrook, PA based AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally.

In September 2017, the companys AmerisourceBergen Specialty Group unit pleaded guilty to a misdemeanor related to the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors, and paid $260 million in criminal fines and forfeitures. AmerisourceBergen Corporation also entered a five-year corporate integrity agreement to ensure compliance with federal health care rules.
On October 1, 2018, the U.S. Department of Justice (DOJ) announced that AmerisourceBergen Corporation will pay $625 million to resolve civil fraud charges over related conduct, bringing AmerisourceBergens total payments to $885 million over its repackaging and distribution of pre-filled syringes that were not approved by the U.S. Food and Drug Administration.